Portal de Periódicos da CAPES

Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms–biologically plausible but clinically uncertain

2009; Wiley; Volume: 85; Issue: 2 Linguagem: Inglês

10.1002/ajh.21614

1096-8652

Ayalew Tefferi,

Kruppel-like factors research

American Journal of HematologyVolume 85, Issue 2 p. 93-94 CommentaryFree Access Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms–biologically plausible but clinically uncertain Ayalew Tefferi, Corresponding Author Ayalew Tefferi [email protected] Division of Hematology, Mayo Clinic, Rochester, MNDivision of Hematology, Mayo Clinic College of Medicine, Rochester, MN, 200 First Street SW, Rochester, MN 55905Search for more papers by this author Ayalew Tefferi, Corresponding Author Ayalew Tefferi [email protected] Division of Hematology, Mayo Clinic, Rochester, MNDivision of Hematology, Mayo Clinic College of Medicine, Rochester, MN, 200 First Street SW, Rochester, MN 55905Search for more papers by this author First published: 15 December 2009 https://doi.org/10.1002/ajh.21614Citations: 3AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Marchioli R,Finazzi G,Landolfi R,Kutti J,Gisslinger H,Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224– 2232. 2 Passamonti F,Rumi E,Pungolino E,Malabarba L,Bertazzoni P,Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117: 755– 761. 3 Alvarez-Larran A,Arellano-Rodrigo E,Reverter JC,Domingo A,Villamor N,Colomer D, et al. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol 2008; 87: 269– 276. 4 Barbui T,Carobbio A,Cervantes F,Vannucchi AM,Guglielmelli P,Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2009: blood-2009–2008–238956. 5 Cervantes F,Alvarez-Larran A,Arellano-Rodrigo E,Granell M,Domingo A,Montserrat E. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia 2006; 20: 55– 60. 6 Passamonti F,Rumi E,Arcaini L,Boveri E,Elena C,Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008; 93: 1645– 1651. 7 Gangat N,Strand J,Li CY,Wu W,Pardanani A,Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007; 138: 354– 358. 8 Wolanskyj AP,Schwager SM,McClure RF,Larson DR,Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 81: 159– 166. 9 Di Nisio M,Barbui T,Di Gennaro L,Borrelli G,Finazzi G,Landolfi R, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007; 136: 249– 259. 10 Barbui T,Carobbio A,Rambaldi A,Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009; 114: 759– 763. 11 Tefferi A,Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33: 313– 320. 12 Kwaan HC,Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost 2003; 29: 451– 458. 13 Wautier MP,El Nemer W,Gane P,Rain JD,Cartron JP,Colin Y, et al. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM. Blood 2007; 110: 894– 901. 14 Trappenburg MC,van Schilfgaarde M,Marchetti M,Spronk HM,ten Cate H,Leyte A, et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica 2009; 94: 911– 918. 15 Santilli F,Romano M,Recchiuti A,Dragani A,Falco A,Lessiani G, et al. Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients. Blood 2008; 112: 1085– 1090. 16 Neunteufl T,Heher S,Stefenelli T,Pabinger I,Gisslinger H. Endothelial dysfunction in patients with polycythaemia vera. Br J Haematol 2001; 115: 354– 359. 17 Falanga A,Marchetti M,Evangelista V,Vignoli A,Licini M,Balicco M, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261– 4266. 18 Falanga A,Marchetti M,Vignoli A,Balducci D,Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33: 523– 530. 19 Maugeri N,Giordano G,Petrilli MP,Fraticelli V,de Gaetano G,Cerletti C, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 2006; 4: 2593– 2598. 20 Marchetti M,Castoldi E,Spronk HM,van Oerle R,Balducci D,Barbui T, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008; 112: 4061– 4068. 21 Kaplar M,Kappelmayer J,Kiss A,Szabo K,Udvardy M. Increased leukocyte-platelet adhesion in chronic myeloproliferative disorders with high platelet counts. Platelets 2000; 11: 183– 184. 22 Maugeri N,Brambilla M,Camera M,Carbone A,Tremoli E,Donati MB, et al. Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation. J Thromb Haemost 2006; 4: 1323– 1330. 23 Kornberg A,Rahimi-Levene N,Yona R,Mor A,Rachmilewitz EA. Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment1+2 levels in patients with polycythemia vera: mechanism of activation of blood coagulation. American Journal of Hematology 1997; 56: 5– 11. 24 Hirahashi J,Mekala D,Van Ziffle J,Xiao L,Saffaripour S,Wagner DD, et al. Mac-1 signaling via Src-family and Syk kinases results in elastase-dependent thrombohemorrhagic vasculopathy. Immunity 2006; 25: 271– 283. 25 Goel MS,Diamond SL. Neutrophil cathepsin G promotes prothrombinase and fibrin formation under flow conditions by activating fibrinogen-adherent platelets. J Biol Chem 2003; 278: 9458– 9463. 26 Tefferi A,Gangat N,Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood 2007; 109: 4105. 27 Gangat N,Wolanskyj AP,Schwager SM,Hanson CA,Tefferi A. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer 2009; 115: 5740– 5745. 28 Landolfi R,Di Gennaro L,Barbui T,De Stefano V,Finazzi G,Marfisi R, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109: 2446– 2452. 29 Carobbio A,Finazzi G,Guerini V,Spinelli O,Delaini F,Marchioli R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109: 2310– 2313. 30 Carobbio A,Antonioli E,Guglielmelli P,Vannucchi AM,Delaini F,Guerini V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26: 2732– 2736. 31 Carobbio A,Finazzi G,Antonioli E,Guglielmelli P,Vannucchi AM,Delaini F, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood 2008; 112: 3135– 3137. 32 De Stefano V,Za T, E. R,Vannucchi A,Ruggeri M, al. e. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. American Journal of Hematology, in press 2010. 33 De Stefano V,Za T,Rossi E,Vannucchi AM,Ruggeri M,Elli E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008; 93: 372– 380. 34 Passamonti F,Rumi E,Pascutto C,Cazzola M,Lazzarino M. Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. J Thromb Haemost 2009; 7: 1587– 1589. 35 Kiladjian JJ,Gardin C,Renoux M,Bruno F,Bernard JF. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J 2003; 4: 198– 207. 36 Gangat N,Wolanskyj AP,McClure RF,Li CY,Schwager S,Wu W, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270– 276. 37 Cervantes F,Dupriez B,Pereira A,Passamonti F,Reilly JT,Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895– 2901. 38 Huang J,Li CY,Mesa RA,Wu W,Hanson CA,Pardanani A, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008; 112: 2726– 2732. Citing Literature Volume85, Issue2February 2010Pages 93-94 ReferencesRelatedInformation